Drug Trial Radar · NCT05586776
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,700
Planned (sponsor's estimate)
Start
Jan 17, 2023
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- University of California, IrvineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of California, Davis; University of California, San Francisco; University of Massachusetts, Amherst; Hoag Memorial Hospital Presbyterian
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.
Conditions
- Surgical Site Infection
Interventions
4% Chlorhexidine GluconateDrug
Used for daily showering/bathing for 30 days after hospital discharge.
2% MupirocinDrug
Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Soap Without Antiseptic Properties (Placebo)Drug
Used for daily showering/bathing for 30 days after hospital discharge.
Placebo Nasal OintmentDrug
Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Post-Discharge Surgical Site InfectionTime frame: Within 30 Days of Hospital Discharge
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
University of California, Irvine Medical Center
Orange, California · Recruiting
University of California, Davis Medical Center
Sacramento, California · Recruiting
University of California, San Francisco Medical Center
San Francisco, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.